SSPN formulations of novel emtricitabine

Status:
Phase:Pre-clinical
Principal Investigator(s):
Objective:Preclinical assessment of LAI semi-solid prodrug nanoparticle (SSPN) formulations of novel emtricitabine (FTC) prodrugs to prevent HIV infection.
Prevention Option(s):PrEP
Study Design:
Arms and Assigned Interventions
DescriptionAnimals received 140 mg/kg FTC equivalent (SSPN 9 or 10) via 2 intramuscular injections vs an untreated control (n= 7-6 per group).
Mode of DeliveryBiojector
ARMs
Related Publications:
LONG-ACTING EMTRICITABINE PRODRUGS PROVIDE PROTECTION FROM HIV INFECTION IN VIVO
Start Date
End Date
none
none
Enrollment:0
Age range: ↔ any
Population: